Journals / Turkish Thoracic Journal / 2021 / Cilt: 22 - Sayı: 2

Managing Lung Cancer during Coronavirus Disease 2019 Pandemic

Pages
163–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a pandemic by the World Health Organization.
📊
Key Findings & Data:As this disease continues to spread worldwide, it has posed enormous challenges on the healthcare of several diseases, especially cancer, because hospital facilities have invested health resources for patients with COVID-19.
💡
Conclusion & Impact:It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a pandemic by the World Health Organization. As this disease continues to spread worldwide, it has posed enormous challenges on the healthcare of several diseases, especially cancer, because hospital facilities have invested health resources for patients with COVID-19. In deed, patients with lung cancer are particularly vulnerable because of their poor baseline lung function and cancer-related treatment. In ad dition, once infected, they are at an increased risk of pulmonary complications from COVID-19. Oncologists are thus facing a challenge as how to balance the treatment plans to control the disease while protecting the patients with lung cancer from COVID-19. In fact, it is crucial to provide individualized treatment recommendations to limit the risks during these difficult times. This review highlights the key challenges that oncologists face when diagnosing COVID-19 among patients with lung cancer and examines the current recommendations from avail able literature, clinical expertise, and expert opinions regarding managing lung cancer in the era of COVID-19. It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection.

🔖

Cite This Article

KHALIFEH, Y. I., TFAYLI, A. H. (2021). Managing Lung Cancer during Coronavirus Disease 2019 Pandemic. Turkish Thoracic Journal, Cilt: 22 - Sayı: 2, 163–168. https://ajindex.com/articles/417916

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin Oncol 2019
  2. [CrossRef] 2. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature reviews Microbiology 2016
  3. [CrossRef] 3. Bonilla-Aldana DK, Quintero-Rada K, Montoya-Posada JP, et al. SARS-CoV, MERS-CoV and now the 2019-novel CoV: Have we investigated enough about coronaviruses? - A bibliometric analysis. Travel medicine and infectious disease. Travel Med Infect Dis 2020
  4. 101566. [CrossRef] 4. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020
  5. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020
  6. Lu R, Zhao X, Li J, Niu P, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020
  7. [CrossRef] 7. WHO. 2020. WHO Director-General’s opening remarks at the media briefing on COVID-19. 8. Bitar N, Kattsn J, Kourie HR, Mukherji D, El Saghir N. The Lebanese society of medical oncology (LSMO) statement on the Care of Patients with Cancer during the COVID-19 Pandemic. Future Oncol 2020
  8. [CrossRef] 9. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020
  9. 101623. [CrossRef] 10. Yang L, Xu HY, Wang Y. Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19). Zhonghua zhong liu za zhi 2020
  10. E006. PubMed PMID: 32118394. 11. Xu Y, Liu H, Hu K, Wang M. Clinical management of lung cancer patients during the outbreak of 2019 Novel Coronavirus Disease (COVID-19). Zhongguo Fei Ai Za Zhi 2020
  11. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology. 2020
  12. [CrossRef] 13. Passaro A, Peters S, Mok TSK, Attili I, Mitsudomi T, de Marinis F. Testing for COVID-19 in lung cancer patients. Ann Oncol 2020
  13. [CrossRef] 14. Ai T, Yang Z, Hou H, et al. Correlation of chest CT